BASEL, Switzerland, Feb. 10 /PRNewswire-FirstCall/ - Neuro-Biotech Corp. (PINKSHEET: MRES) (OTCQB: MRES) Dr Claude Poulin is pleased to announce that on February 9, MRES has received an unsolicited offer for the purchase of all the outstanding shares at $0.15 per share.
Management is currently conducting due diligence and should be able to provide to its shareholders further details by Tuesday February 15. The company making the offer, with expertise similar to Neuro-Biotech, is exclusively contracted by military forces to research and develop new type of medications.
For more information on Neuro-Biotech Corp or to contact a company representative, please visit: www.neuro-biotechcorp.com
FORWARD LOOKING STATEMENTS
This release contains statements that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Act of 1995. Certain statements in this press release may contain words such as "anticipates," "believes," "could," "expects," "intends," "may," "projects," "targets" and other similar language that is considered forward-looking statements. These forward-looking statements are subject to certain risks and uncertainties and persons reading this release are cautioned that such statements are only predictions, and that the Company's actual future results or performance may be materially different. The Company disclaims any intention or obligation to update or revise forward-looking information, whether as a result of new information, future events, or otherwise, could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
SOURCE Neuro-Biotech Corp.